Introduction to Blood Storage Solutions in Pediatric Care

Maintaining AS-3 blood transfusion safety is a major priority for pediatric cardiac surgeons and anesthesiologists managing complex cases. Traditionally, clinicians used red blood cells stored in anticoagulant-citrate-phosphate-dextrose (CPD) for large-volume transfusions (LVT). Many centers hesitated to adopt additive solutions like AS-3 for infants due to potential metabolic risks. However, recent evidence suggests that these concerns may not translate into adverse clinical outcomes. Specifically, a retrospective review examined the impact of transitioning from CPD to AS-3 products in high-risk procedures.

Metabolic Impact of Additive Solutions

The study analyzed 89 pediatric patients undergoing Norwood procedures or heart transplants. Researchers monitored laboratory values before surgery, immediately afterward, and one day later. Notably, patients receiving AS-3 products showed significantly higher levels of sodium, glucose, and phosphorus immediately post-surgery. Furthermore, lactate levels varied depending on the procedure. Infants undergoing the Norwood procedure in the AS-3 group had higher lactate, likely due to their younger age. Conversely, heart transplant recipients in the AS-3 group exhibited lower lactate levels immediately and on the first postoperative day.

AS-3 Blood Transfusion Safety and Clinical Outcomes

Crucially, these metabolic shifts were transient. All laboratory abnormalities associated with the additive solution fully resolved within 24 hours. Consequently, the study found no significant differences in mortality between the CPD and AS-3 groups. Additionally, the total length of stay (LOS) and intensive care unit (ICU) duration remained consistent across both cohorts. Therefore, the results support the safe use of AS-3 stored products even in the context of large-volume pediatric transfusions. This transition potentially simplifies blood bank inventory management without compromising patient care.

Conclusion and Clinical Implications

In summary, while AS-3 solutions introduce temporary electrolyte and glucose changes, they do not appear to impact long-term recovery or survival. Surgeons and anesthesiologists can feel more confident in the safety profile of these modern blood storage methods. This analysis provides essential data for hospitals considering a switch from traditional anticoagulant storage to more versatile additive solutions for neonatal and pediatric cardiac care.

Frequently Asked Questions

Does AS-3 storage affect mortality in pediatric heart surgery?

No, the study demonstrated that mortality rates were similar between the CPD and AS-3 groups, indicating that the choice of storage solution does not impact survival outcomes.

What metabolic changes are associated with AS-3 transfusions?

Patients may experience transient increases in sodium, glucose, and phosphorus immediately after a large-volume transfusion. However, these levels typically return to normal within 24 hours.

Is AS-3 safer than CPD for neonates?

The study suggests that AS-3 is a safe alternative to CPD. While it causes minor laboratory fluctuations, it offers similar clinical safety in terms of hospital stay and mortality.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Clinicians should use their professional judgment and consider individual patient factors. Refer to the latest local and national guidelines for clinical practice.

References

Saifee NH et al. Red blood cells stored in anticoagulant versus additive solution for large volume transfusions in pediatric patients undergoing cardiopulmonary bypass. Transfusion. 2026 Jun 18. doi: 10.1111/trf.70297. PMID: 42313418.

Strauss RG et al. AS-1 red cells for neonatal transfusions: A randomized trial assessing donor exposure and safety. Transfusion 1996;36:873-8.

New HV et al. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol 2016;175:784-828.